Abbott XIENCE Xpedition Everolimus Eluting Coronary Stent System

Abbott XIENCE Xpedition Drug-Eluting Coronary Stent System

The Abbott XIENCE Xpedition Everolimus-Eluting Coronary Stent System is an advanced drug-eluting stent (DES) designed to treat coronary artery disease (CAD) during percutaneous coronary intervention (PCI) procedures.
Developed as part of the globally recognized XIENCE™ family of coronary stents, the Xpedition system combines proven clinical outcomes, enhanced deliverability, and innovative stent architecture to help physicians effectively restore blood flow in narrowed coronary arteries.

Built on Abbott’s trusted MULTI-LINK™ stent design, the XIENCE Xpedition stent offers a strong yet flexible platform that provides excellent vessel support while adapting to complex coronary anatomy.
The stent is mounted on a specialized balloon catheter that enables accurate lesion expansion and helps ensure secure stent apposition against the vessel wall during angioplasty procedures.

The system uses everolimus, a well-established antiproliferative drug that helps inhibit excessive tissue growth within the artery, reducing the risk of restenosis following stent implantation.
The XIENCE drug-eluting stent platform has been extensively studied in clinical trials involving tens of thousands of patients, demonstrating strong safety outcomes and long-term effectiveness in coronary revascularization.

The low-profile stent delivery catheter enhances crossability and allows smooth navigation through tortuous coronary vessels and challenging lesions.
This design improves procedural efficiency and helps interventional cardiologists reach difficult-to-treat blockages with greater confidence.

Available in a broad range of stent diameters and lengths, the XIENCE Xpedition system allows physicians to select the appropriate size for different coronary vessel anatomies and lesion types, supporting optimal treatment outcomes during PCI procedures.

Key Features
Everolimus-Eluting Drug Technology: The stent releases everolimus to inhibit smooth muscle cell proliferation and reduce the risk of restenosis following coronary angioplasty.
MULTI-LINK™ Stent Architecture: A proven stent platform designed to provide strength, flexibility, and reliable vessel scaffolding in complex coronary anatomy.
Enhanced Deliverability System: A redesigned low-profile catheter improves trackability and facilitates navigation through challenging coronary lesions.
Broad Size Matrix: Stent diameters typically range from 2.25 mm to 4.0 mm (including 3.25 mm options) and lengths from 8 mm to 38 mm, allowing precise vessel sizing.
Supported by Extensive Clinical Evidence: Part of the XIENCE family of drug-eluting stents with clinical data from over 45,000 patients and more than 100 studies, demonstrating long-term safety and effectiveness.
Direct Stenting Capability: Proven safe for direct stenting techniques, potentially reducing procedure time and device use in the catheterization laboratory.

Clinical Applications
Treatment of coronary artery disease (CAD)
Percutaneous coronary intervention (PCI)
Treatment of de novo coronary artery lesions
Coronary revascularization in patients with symptomatic heart disease
Management of complex coronary lesions

Product Information
Brand: Abbott
Product: XIENCE Xpedition Drug-Eluting Coronary Stent System
Category: Drug-Eluting Coronary Stent (DES)
Drug: Everolimus
Stent Design: MULTI-LINK™ platform
Stent Diameter Range: 2.25 – 4.0 mm
Stent Length Range: 8 – 38 mm
Application: Coronary Angioplasty & Percutaneous Coronary Intervention